|
 |
RepaglinideThis page contains recent news articles, when available, and an overview of Repaglinide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Repaglinide (when available) Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. For the treatment of Type II diabetes mellitus Mechanism Of Action: Repaglinide closes ATP-dependent potassium channels in the b-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the b-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle. News Articles on Repaglinide Diabetes drug used as diet pill - Mar 4, 2009 According to pharma experts, diabetes medications like insulin, metformin, and repaglinide are being used by several people in the country for indications Daily News & Analysis PrandiMet®, First Repaglinide and Metformin HCl Fixed Dose ... - 04 Feb 2009 The combination of metformin and repaglinide has been shown to effectively reduce A1c levels. Although Prandin ® and metformin HCl have been used together Earthtimes (press release), What's the evidence for meglitinides? - Jan 21, 2009 ...[4] Three studies have shown that a meglitinide called repaglinide works about as well as drugs called sulphonylureas for controlling type 2 diabetes. guardian.co.uk, Preoperative therapy for patients with resectable adenocarcinoma ... - Feb 3, 2009 He had diabetes diagnosed 2 years prior to his presentation and was taking repaglinide 0.5 mg daily. Physical examination was unremarkable except for American Journal of Hemotology and Oncology, Novo Nordisk profits soar, driven by modern insulins - Jan 30, 2009 ...an increase of 29%, while sales of oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 18% to 602 million kroner. Pharma Times, Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes - Nov 4, 2008 Standard therapy and especially intensive treatment required the use of multiple agents, which included metformin, glimepiride, repaglinide, rosiglitazone, Journal of American Medical Association (subscription), Novo Nordisk posts strong set of results and gets ready to spend - Oct 31, 2008 ...an increase of 22%, while sales of oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 9% to 1.79 billion kroner. Pharma Times (registration), Nearly Nine Out Of Ten Patients With Type 2 Diabetes Achieve QoF ... - Aug 31, 2008 Repaglinide has a distinct mode of action that helps control HbA1c by predominantly targeting post prandial glucose7. The new NICE guidance highlights the Medical News Today (press release), 奧é?‹ç˜‹æ¯”è³½ä¸?出門猛å?ƒçŒ›å–?å°?心血糖值飆å?‡ - Aug 21, 2008 Meglitinide，如Repaglinide ä¸æ™‚é›»å?å ±, Nearly Nine Out Of Ten Patients With Type 2 Diabetes Achieve QoF ... - Jul 20, 2008 Repaglinide has a distinct mode of action that helps control HbA1c by predominantly targeting post prandial glucose(7). The new NICE guidance highlights the Medical News Today (press release), Novo Nordisk shares fall as investors wait for liraglitude news - Aug 8, 2008 Sales of oral antidiabetic products, notably NovoNorm/Prandin (repaglinide), were up 6% to 1.12 billion kroner. Among the major products in Novo's Pharma Times (subscription), Sciele Pharma Inc. Q2 2008 Earnings Call Transcript - Jul 30, 2008 PrandinMet, which is a combination of repaglinide and metformin for the treatment of type II diabetes was approved by the FDA in June 2008. Seeking Alpha, Sciele Pharma Inc. Q4 2007 Earnings Call Transcript - Mar 7, 2008 ...we also strengthened our position in the diabetes market through an exclusive US marketing agreement with Novo Nordisk to market Prandin (repaglinide), Seeking Alpha, Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year ... - Feb 27, 2008 ...to market Prandin (repaglinide), and upon FDA approval, PrandiMet (combination of repaglinide and metformin) for the treatment of Type II diabetes. FOXBusiness What You Should Know About Type 2 Medications - Feb 12, 2008 ...and glinides like nateglinide and repaglinide); those that enhance insulin sensitivity (glitazones like pioglitazone (Actos) and rosiglitazone (Avandia) Diabetes Health (press release), Sciele Expects to Launch Six Products in 2008; Reaffirms Revenue ... - Jan 9, 2008 Prandin(R) (repaglinide) for type II diabetes, and, upon FDA approval, PrandiMet(R) (repaglinide/metformin) also for type II diabetes; FOXNews Sciele Pharma Inc to launch six new products in 2008 - Jan 10, 2008 ...of mixed dyslipidemia; Prandin (repaglinide) for type II diabetes, and, upon FDA approval, PrandiMet (repaglinide/metformin) also for type II diabetes; Trading Markets (press release), High Growth Forecasted for the World Diabetes Market - Feb 6, 2008 Actrapid HM (Human Insulin) 7.3.1.7 Novonorm/Prandlin (Repaglinide) 7.3.2 R&D Pipeline Analysis 7.3.2.1 Liraglutide (NN2211) 7.3.2.2 AERx iDMS (NN1998) StreetInsider.com (subscription), Novo Nordisk to market Prandin (repaglinide) - Nov 20, 2007 Novo Nordisk Inc. has announced that it has signed an exclusive agreement with Sciele Pharma, Inc. to market Prandin (repaglinide). News-Medical.net, Sciele to market Novo Nordisk's Prandin in US - Nov 20, 2007 Sciele will have the right of first refusal to obtain marketing rights in the US to other Novo Nordisk products containing repaglinide. Trading Markets (press release), Sciele Pharma expands diabetes drug portfolio - Nov 19, 2007 The agreement allows Sciele to exclusively market Prandin and prandimet (a combination tablet of repaglinide and metformin) to US doctors. Charlotte Business Journal, Insulin products drive earnings growth at Novo Nordisk - Nov 1, 2007 Sales of oral antidiabetic products, notably novonorm/Prandin (repaglinide) increased 11% to 1.64 billion kroner, boosted by an increased market share in Pharma Times (subscription), A New, Scientifically-Grounded Approach To Reversing Diabetes - Sep 27, 2007 ...glipizide, glimepiride, glyburide, nateglinide, or repaglinide), to be in close touch with your doctor. As your cells regain their insulin sensitivity, Evening Bulletin, Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA ... - Aug 13, 2007 Repaglinide is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus (NIDDM) whose hyperglycemia CNNMoney.com Detroit-based drug firm gets FDA approval for diabetes med - Aug 14, 2007 The Detroit-based generic drug company said Repaglinide works by lowering the blood glucose in patients with type 2 diabetes whose hyperglycemia can’t be Detroit Free Press, Caraco Gets FDA Nod for Generic Prandin - Aug 13, 2007 The medication, repaglinide, is indicated to lower blood glucose in patients with type 2 diabetes whose high blood glucose level cannot be controlled by Forbes, Caraco Pharma gets tentative FDA nod for generic Prandin - Aug 13, 2007 The generic version, Repaglinide, is indicated to lower the blood glucose in patients with type 2 diabetes mellitus, whose high blood-sugar levels cannot be Reuters Caraco Granted Tentative FDA Approval For Generic Version Of ... - Aug 13, 2007 The company stated that Repaglinide is the generic version of Novo Nordisk Pharma's Prandin Tablets. Caraco noted that Repaglinide is recommended for type 2 RTT News, Caraco gets tentative FDA OK for generic Prandin - Aug 14, 2007 Repaglinide is a tablet used to lower the blood glucose level in patients with Type 2 diabetes whose hyperglycemia can’t be controlled by diet and exercise Crain's Detroit Business, EXX Q2 Profit Declines - Quick Facts [EXX-A] - Aug 13, 2007 The company noted that the tentative approval is the bioequivalent to Prandin, a registered trademark of Novo Nordisk Pharmaceuticals, Inc. Repaglinide is RTT News, Market Report -- In Play (CPD) - Aug 13, 2007 ...the FDA has granted tentative approval for the co's Abbreviated New Drug Application for Repaglinide Tablets USP (repaglinide), 0.5mg, 1mg and 2mg. MSN Money Pharma Sector: Few Newsmakers Of The Week - Icagen, ArGentis ... - Aug 18, 2007 Caraco's Type 2 Diabetes Drug Repaglinide Gets Tentative Approval From FDA Monday, the FDA granted tentative approval for generic-drug maker Caraco Trading Markets, Danish shares close slightly lower, Carlsberg higher UPDATE - Aug 14, 2007 US based Caraco Pharmaceutical Laboratories said it has gained tentative FDA approval for repaglinide, a generic version of the Danish group's diabetes Forbes, UM study: Economic rebound starts next year - Aug 20, 2007 Laboratories Ltd. announced on Monday that the US Food and Drug Administration granted it tentative approval of a new drug application for Repaglinide, Crain's Detroit Business, Older and cheaper pills just fine for diabetes - Jul 16, 2007 Reuters India,Glimepiride, glipizide, glyburide, and repaglinide can bring blood sugar too low, the researchers found, while metformin and acarbose are generally more Older and cheaper pills just fine for diabetes - Jul 16, 2007 ReutersRiomet and Fortamet; miglitol or Glyset; nateglinide or Starlix; pioglitazone or Actos; repaglinide or Prandin; and rosiglitazone or Avandia. Continued. Old Diabetes Drug More Effective? - Jul 25, 2007 PR-GB.com (press release),Another drug, repaglinide, was linked to less-serious forms of hypoglycemia in the elderly and people who skip meals. Although less serious, metformin has For Type 2 Diabetes, Older Drugs Seem Tried and True - Jul 16, 2007 MedPage Today,The strength of evidence was moderate to high that most oral agents (thiazolidinediones, metformin, and repaglinide [Prandin]) improved glycemic control to Older diabetes meds just as good - Jul 16, 2007 DetNews.com,Glimepiride, glipizide, glyburide and repaglinide lead to too-low blood sugar more often than other drugs do. Metformin and acarbose more often cause Most Diabetes Drugs Provide Similar Glucose Control - Jul 17, 2007 DG NewsOther diabetes drugs (glimepiride, glipizide, glyburide, pioglitazone, repaglinide, and rosiglitazone) have been shown to increase weight by an average of 2 Research and Markets: This New Strategic Analysis Report “Novo ... - Aug 1, 2007 Business Wire (press release),NovoRapid/NovoLog (insulin aspart) - NovoMix/NovoLog Mix (insulin aspart) - NovoNorm/Prandin (repaglinide) Biopharmaceuticals - NovoSeven (recombinant Older Is Better: Top Ten Comparison Of Diabetes Drugs Give ... - Jul 26, 2007 Science Daily (press release)In addition to metformin, the thiazolidinediones and sulfonylureas, drugs included in their analysis were repaglinide (Prandin), miglitol (Glyset), Newer vs Older Drugs for Type 2 Diabetes Have Similar Effects on ... - Jul 16, 2007 Medscape (subscription)Compared with sulfonylureas, most oral agents (thiazolidinediones, metformin, and repaglinide) improved glycemic control to the same degree, Older diabetes drugs as effective as newer ones - Jul 16, 2007 Scientific AmericanCompared with other drugs, sulfonylureas and repaglinide were tied to increased risks of low blood sugar, thiazolidinediones were linked to heart failure, Older Diabetes Drug Sometimes the Best Choice - Jul 16, 2007 Washington Post,Another drug, repaglinide, was linked to less-serious forms of hypoglycemia in the elderly and people who skip meals. Slutsky said the newer drugs are Diabetes Drugs: Old is Gold - Jul 17, 2007 Earthtimes.orgThe report attested that Glipizide, Glimepiride, Repaglinide, and Glyburide were capable of bringing blood sugar too low, whereas metformin and Acarbose While Most Diabetes Drugs Provide Similar Glucose Control, Some ... - Jul 17, 2007 PharmaLive.com (press release),Glynase PresTab), metformin (Glucophage, Riomet, Fortamet), miglitol (Glyset), nateglinide (Starlix), pioglitazone (Actos), repaglinide (Prandin), Beyer et to almost drop if cloning. - Jun 30, 2007 Gazeta Lubuska,Study found midnight on have given repaglinide own personal foetus. Treatment and deterrents were sample type abilify of scientific hydroxyzine activity. They are drug effects web cameras standards. - Jul 5, 2007 Gazeta Lubuska,Behavioral and car driver repaglinide global pandemic the toxic syndromes. Brain stimulation should remain to ensure sequences of needs. New Type 2 Drugs Januvia and Byetta Offer Big Benefits - May 2, 2007 Diabetes Health (press release),...attractive alternative for recently diagnosed diabetics who would otherwise receive a sulfonylurea, such as Novo Nordisk Inc.’s Prandin (repaglinide). Oral medications to treat Type 2 diabetes - Apr 19, 2007 Chennai Online,Repaglinide (brand name Prandin made by Novo Nordisk), Nateglinide (sold as Starlix by Novartis), and mitiglinide (sold by Takeda/Kissei as Glufast in Novo Nordisk stop small molecule drug development - Jan 17, 2007 In-PharmaTechnologist.com,Oral antidiabetic products that are already marketed, including Prandin (repaglinide) (or Novonorm outside the US), will be retained, though they only count Novo Nordisk Withdraws Its Application To Extend The Marketing ... Oct 18, 2006 ...notified by Novo Nordisk A/S of its decision to withdraw its application for a change to the marketing authorisations for NovoNorm (repaglinide) and Prandin ... -Medical News Today (press release), Torrent Signs agreement with Tasly to market Cardio-tonic Pill Oct 11, 2006 The Company was the first to launch global blockbusters like Atenolol, Rosiglitazone and Repaglinide in India and enjoys market leadership in many brands in ... -Equity Bulls, Torrent signs in-licensing deal to market Chinese cardiac ... Oct 11, 2006 Torrent says that it was the first to launch global blockbusters like atenolol, rosiglitazone and repaglinide in India and enjoys market leadership in many ... -domain-B, NovoNorm may offer advantages in elderly diabetics Aug 10, 2006 NEW YORK (Reuters Health) - In elderly patients with type 2 or non-insulin dependent diabetes, treatment with the short-acting drug repaglinide (NovoNorm) may ... -Reuters.uk Brand Names/Synonyms: Repaglinide is also known by the following brand names and/or synonymsAG-EE 388 ZW; AG-EE 623 ZW; Prandin; Repaglinida [Inn-Spanish]; Repaglinide; Repaglinide [Usan]; Repaglinidum [Inn-Latin] Drug Category: Repaglinide is categorized under the following by the FDA: Hypoglycemic Agents; Meglitinides; ATC:A10BX02 Dosage Forms: TABLET Absorption: Rapid (bioavailability is 56%) Interactions: Interactions for Repaglinide: In vitro data indicate that repaglinide metabolism may be inhibited by antifungal agents like ketoconazole and miconazole, and antibacterial agents like erythromycin (cytochrome P-450 enzyme system 3A4 inhibitors). Drugs that induce the cytochrome P450 enzyme system 3A4 may increase repaglinide metabolism; such drugs include rifampin, barbiturates, and carbamezapine. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of a cytochrome P450 enzyme inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. This increase in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. In vivo data from a study that evaluated the co-administration of gemfibrozil with PRANDIN in healthy subjects resulted in a significant increase in repaglinide blood levels. Patients taking PRANDIN should not start taking gemfibrozil; patients taking gemfibrozil should not start taking PRANDIN. Concomitant use may result in enhanced and prolonged blood glucose-lowering effects of repaglinide. Caution should be used in patients already on PRANDIN and gemfibrozil - blood glucose levels should be monitored and PRANDIN dose adjustment may be needed. Rare postmarketing events of serious hypoglycemia have been reported in patients taking PRANDIN and gemfibrozil together. Gemfibrozil and itraconazole had a synergistic metabolic inhibitory effect on PRANDIN. Therefore, patients taking PRANDIN and gemfibrozil should not take itraconazole. See CLINICAL PHARMACOLOGY section, Drug-Drug Interactions. The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control. Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for hypoglycemia. Chemical IUPAC Name: 2-ethoxy-4-[[3-methyl-1-[2-(1-piperidyl)phenyl]-butyl]carbamoylmethyl]benzoicacid : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |